111 related articles for article (PubMed ID: 27506415)
1. Short-term versus longer duration of glucocorticoid therapy for exacerbations of chronic obstructive pulmonary disease.
Ma Z; Zhang W
Pulm Pharmacol Ther; 2016 Oct; 40():84-90. PubMed ID: 27506415
[TBL] [Abstract][Full Text] [Related]
2. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease.
Walters JA; Wang W; Morley C; Soltani A; Wood-Baker R
Cochrane Database Syst Rev; 2011 Oct; (10):CD006897. PubMed ID: 21975757
[TBL] [Abstract][Full Text] [Related]
3. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease.
Walters JA; Tan DJ; White CJ; Wood-Baker R
Cochrane Database Syst Rev; 2014 Dec; (12):CD006897. PubMed ID: 25491891
[TBL] [Abstract][Full Text] [Related]
4. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease.
Walters JA; Tan DJ; White CJ; Wood-Baker R
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD006897. PubMed ID: 29553157
[TBL] [Abstract][Full Text] [Related]
5. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial.
Leuppi JD; Schuetz P; Bingisser R; Bodmer M; Briel M; Drescher T; Duerring U; Henzen C; Leibbrandt Y; Maier S; Miedinger D; Müller B; Scherr A; Schindler C; Stoeckli R; Viatte S; von Garnier C; Tamm M; Rutishauser J
JAMA; 2013 Jun; 309(21):2223-31. PubMed ID: 23695200
[TBL] [Abstract][Full Text] [Related]
6. Short versus conventional term glucocorticoid therapy in acute exacerbation of chronic obstructive pulmonary disease - the "REDUCE" trial.
Schuetz P; Leuppi JD; Tamm M; Briel M; Bingisser R; Dürring U; Müller B; Schindler C; Viatte S; Rutishauser J
Swiss Med Wkly; 2010; 140():w13109. PubMed ID: 21136333
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two systemic steroid regimens for the treatment of COPD exacerbations.
Ceviker Y; Sayiner A
Pulm Pharmacol Ther; 2014 Apr; 27(2):179-83. PubMed ID: 23518215
[TBL] [Abstract][Full Text] [Related]
8. Systemic corticosteroid for COPD exacerbations, whether the higher dose is better? A meta-analysis of randomized controlled trials.
Cheng T; Gong Y; Guo Y; Cheng Q; Zhou M; Shi G; Wan H
Clin Respir J; 2013 Oct; 7(4):305-18. PubMed ID: 23072733
[TBL] [Abstract][Full Text] [Related]
9. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
10. Comparative Efficacies of Inhaled Corticosteroids and Systemic Corticosteroids in Treatment of Chronic Obstructive Pulmonary Disease Exacerbations: A Systematic Review and Meta-Analysis.
Zhai Y; Zhang H; Sun T; Ye M; Liu H; Zheng R
J Aerosol Med Pulm Drug Deliv; 2017 Oct; 30(5):289-298. PubMed ID: 28300474
[TBL] [Abstract][Full Text] [Related]
11. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
[TBL] [Abstract][Full Text] [Related]
12. [Meta-analysis and trial sequential analysis of modified Sangbaipi Decoction for treating acute exacerbation of chronic obstructive pulmonary disease].
Zheng WJ; Peng ZJ; Yan Q; Zhang CY; Liu BE; Hong Y; Liu XH
Zhongguo Zhong Yao Za Zhi; 2019 Sep; 44(17):3806-3815. PubMed ID: 31602957
[TBL] [Abstract][Full Text] [Related]
13. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
Kuna P; Jenkins M; O'Brien CD; Fahy WA
Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578
[TBL] [Abstract][Full Text] [Related]
14. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
[TBL] [Abstract][Full Text] [Related]
15. Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD.
Calverley PM; Eriksson G; Jenkins CR; Anzueto AR; Make BJ; Persson A; Fagerås M; Postma DS
Int J Chron Obstruct Pulmon Dis; 2017; 12():13-25. PubMed ID: 28031707
[TBL] [Abstract][Full Text] [Related]
16. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
Sobieraj DM; White CM; Coleman CI
Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
[TBL] [Abstract][Full Text] [Related]
17. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group.
Niewoehner DE; Erbland ML; Deupree RH; Collins D; Gross NJ; Light RW; Anderson P; Morgan NA
N Engl J Med; 1999 Jun; 340(25):1941-7. PubMed ID: 10379017
[TBL] [Abstract][Full Text] [Related]
18. A score to predict short-term risk of COPD exacerbations (SCOPEX).
Make BJ; Eriksson G; Calverley PM; Jenkins CR; Postma DS; Peterson S; Östlund O; Anzueto A
Int J Chron Obstruct Pulmon Dis; 2015; 10():201-9. PubMed ID: 25670896
[TBL] [Abstract][Full Text] [Related]
19. Withdrawal of inhaled glucocorticoids and exacerbations of COPD.
Magnussen H; Disse B; Rodriguez-Roisin R; Kirsten A; Watz H; Tetzlaff K; Towse L; Finnigan H; Dahl R; Decramer M; Chanez P; Wouters EF; Calverley PM;
N Engl J Med; 2014 Oct; 371(14):1285-94. PubMed ID: 25196117
[TBL] [Abstract][Full Text] [Related]
20. The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review.
Fowdar K; Chen H; He Z; Zhang J; Zhong X; Zhang J; Li M; Bai J
Heart Lung; 2017; 46(2):120-128. PubMed ID: 28109565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
